[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645708":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":90,"collaborators":10,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":10,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":10,"studyType":105,"phases":10,"briefSummary":106,"conditions":107,"keywords":112,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Neurogen Biomarking LLC","INDUSTRY",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"AD subjects",null,"Amyloid PET\u002FCSF confirmed and clinically diagnosed",{"label":13,"type":10,"description":14,"interventionNames":10},"Healthy Controls","No history of cognitive impairment",{"label":16,"type":10,"description":17,"interventionNames":10},"Non-AD cognitively impaired (amyloid-negative)","Cognitive impairment not due to AD, confirmed amyloid-negative via PET\u002FCSF",[19],{"name":20,"affiliation":21,"role":22},"Rany Aburashed","Insight Health Systems","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Ansam Eghzawi, MD","CONTACT","+18109410076","ansam@neurogenbiomarking.com",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Elisabeth Thijssen, PhD","+16282788161","elisabeth@neurogenbiomarking.com",[34,51,62,71,80],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Insigth Hospital and Medical Center Chicago","RECRUITING","Chicago","Illinois","60616","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-87.65005,41.85003,{"lat":46,"lon":45},[49,50],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":40,"countryCode":41,"cosmosGeoPoint":57,"geoPoint":61,"contacts":10},"Insight Hospital and Medical Center Dearborn","ACTIVE_NOT_RECRUITING","Dearborn","Michigan","48126",{"type":43,"coordinates":58},[59,60],-83.17631,42.32226,{"lat":60,"lon":59},{"facility":63,"status":53,"city":64,"state":55,"zip":65,"country":40,"countryCode":41,"cosmosGeoPoint":66,"geoPoint":70,"contacts":10},"Insight Institute of Neurology and Neurosurgery","Flint","48507",{"type":43,"coordinates":67},[68,69],-83.68746,43.01253,{"lat":69,"lon":68},{"facility":72,"status":53,"city":73,"state":55,"zip":74,"country":40,"countryCode":41,"cosmosGeoPoint":75,"geoPoint":79,"contacts":10},"Memorial Healthcare Hospital","Owosso","48867",{"type":43,"coordinates":76},[77,78],-84.17664,42.9978,{"lat":78,"lon":77},{"facility":81,"status":53,"city":82,"state":83,"zip":84,"country":40,"countryCode":41,"cosmosGeoPoint":85,"geoPoint":89,"contacts":10},"Wake Forest Baptist Medical Center","Winston-Salem","North Carolina","27157",{"type":43,"coordinates":86},[87,88],-80.24422,36.09986,{"lat":88,"lon":87},{"type":91,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100645708","development-of-a-home-test-for-measuring-blood-p-tau217-in-alzheimers-disease-using-the-tasso-lancet-device-100645708",false,"NCT07701161","Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device","Inclusion Criteria:\n\n* AD Amyloid PET\u002FCSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent\u002Fassistance available if needed\n\nExclusion Criteria:\n\n* Uncontrolled systemic conditions Recent surgery\u002Fhospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use",true,"ALL","40 Years","90 Years",{"count":103,"type":104},1000,"ESTIMATED","OBSERVATIONAL","This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.",[108,109,110,111],"Alzheimer s Disease","MCI Conversion to Dementia","pTau217","Biomarkers",[113,114,115,116,117],"Alzheimer's disease","Neurogen Biomarking","pTau","MCI","Dementia","2026-07-08",{"date":120,"type":121},"2026-07-14","ACTUAL",{"date":123,"type":121},"2025-01-13",{"date":125,"type":104},"2026-08-01",{"name":5,"class":6},5]